Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NN1558
- Development stage
- Preclinical
- Lead developer
- Novo Nordisk
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
NN1558 is a long-acting dual amylin/calcitonin receptor agonist (DACRA) developed by Novo Nordisk for the treatment of obesity and weight management. It was designed as a stable amylin analog at neutral pH to facilitate co-formulation with other therapeutic peptides, such as GLP-1 receptor agonists. In preclinical studies, NN1558 has been evaluated as a monotherapy and in combination with other agents like liraglutide or FGF21 analogues to assess its effects on food intake, energy expenditure, and body weight in animal models.
02
Targets
AMY receptor (Calcitonin receptor (with ramps))CALCR (Calcitonin receptor)
Beyond the preview
Go deeper on NN1558.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NN1558.